Experts discuss the safety profile and cost of gene therapy for the management of sickle cell disease.
Sophie M. Lanzkron, MD, MHS
Advertisement
Articles by Sophie M. Lanzkron, MD, MHS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
2
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
3
Quarter Century Update: Thoughts on Reducing Costs of Goods
4
Quarter Century Update: Future Predictions for the Field
5
